At the invitation of the editors of Blood, the leading and most prestigious journal in hematology and hemato-oncology, Peter Krenn and Fritz Aberger of CCS have written an article on new therapeutic concepts using so-called Hedgehog inhibitors, which have recently been approved for the treatment of certain solid tumors and leukemias. The authors propose a new innovative therapeutic approach based on targeting the vulnerabilities of aggressive cancer cells and their cancer hallmarks through rational combined drug treatment. The article appears in the latest issue of Blood and can be downloaded at https://authors.elsevier.com/a/1iDKv1UYwjQrj
Comments